Results 21 to 30 of about 47,774 (288)
Molecular Therapy: Nucleic Acids, 2019 Antisense oligonucleotide (AO) therapy has been the specific treatment for Duchenne muscular dystrophy, with ongoing clinical trials. However, therapeutic applications of AOs remain limited, particularly because of the lack of efficient cellular delivery
Mingxing Wang +4 more
doaj +1 more source
Selected strategies to fight pathogenic bacteria
Journal of Enzyme Inhibition and Medicinal Chemistry, 2023 Natural products and analogues are a source of antibacterial drug discovery. Considering drug resistance levels emerging for antibiotics, identification of bacterial metalloenzymes and the synthesis of selective inhibitors are interesting for ...
Aiva Plotniece +13 more
doaj +1 more source
Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes [PDF]
, 1994 Encapsulation of oligonucleotides in antibody-targeted liposomes (immunoliposomes) which bind to target cells permits intracellular delivery of the oligonucleotides.
Zelphati, Olivier +2 more
core +1 more source
, 2023 Nucleic acid therapeutics, specifically antisense oligonucleotides (ASOs), can effectively modulate gene expression and protein function, leading to long-lasting curative effects.
Raghav Gupta +6 more
core +1 more source
Rationally designing antisense therapy to keep up with evolving bacterial resistance.
PLoS ONE, 2019 Antisense molecules used as antibiotics offer the potential to keep up with acquired resistance, by redesigning the sequence of an antisense. Once bacteria acquire resistance by mutating the targeted sequence, new antisense can readily be designed by ...
Seyfullah Kotil, Eric Jakobsson
doaj +1 more source
Expression of ssDNA in Mammalian Cells
BioTechniques, 2003 Antisense therapy involves the use of antisense oligonucleotides for altering targeted gene function. However, the low efficiency of cell delivery of antisense oligonucleotides has limited the efficacy of antisense therapeutic approaches.
Yin Chen, Yong-Jie Ji, Charles Conrad
doaj +1 more source
Molecular Therapy: Nucleic Acids, 2017 We investigated a series of Tween 85 modified low molecular weight polyethylenimine (LPEI, 0.8k/1.2k/2.0k)-copolymers (Zs) through simple formulation and covalent conjugation with phosphorodiamidate morpholino oligomer (PMO) for their potential to ...
Mingxing Wang +6 more
doaj +1 more source
Delivery of Antisense Oligonucleotides to the Mouse Retina [PDF]
, 2022 AbstractThe eye is the organ in charge of vision and, given its properties, has become an excellent organ to test genetic therapies, including antisense oligonucleotide (AON) technology. In fact, the first AON receiving FDA and EMA approval was meant to treat an eye condition.
openaire +3 more sources
Molecular Therapy: Nucleic Acids, 2018 Antisense oligonucleotide (AON) therapy for Duchenne muscular dystrophy has drawn great attention in preclinical and clinical trials, but its therapeutic applications are still limited due to inefficient delivery.
Mingxing Wang +4 more
doaj +1 more source
International Journal of Nanomedicine, 2023 Marta Kutwin,1 Malwina Sosnowska,1 Agnieszka Ostrowska,1 Maciej Trzaskowski,2 Agata Lange,1 Mateusz Wierzbicki,1 Sławomir Jaworski1 1Department of Nanobiotechnology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, 02-786, Poland;
Kutwin M +6 more
doaj